Alexion Pharmaceuticals (ALXN) Revenue and Net Income History
Historical revenue, operating income and net income for Alexion Pharmaceuticals (ALXN) over the last 10 years. The current TTM revenue for Alexion Pharmaceuticals as of March 22, 2018 is $3.55B.
|Medical||Medical - Biomedical and Genetics||$26.134B||$3.551B|
|Alexion Pharmaceuticals, Inc. is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies. Alexion is the global leader in complement inhibition and has developed and commercializes the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG). In addition, Alexion has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D).|